gefitinib has been researched along with Response Evaluation Criteria in Solid Tumors in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Meyers, O; Migliorino, MR; Mok, TS; Nakagawa, K; Niho, S; Paty, J; Płużański, A; Reisman, A; Sandin, R; Wu, YL; Zhou, X | 1 |
| Dong, Y; Li, D; Li, Q; Miao, Q | 1 |
| Berghmans, T; Besse, B; De Maio, E; Dziadziuszko, R; Hasan, B; Menis, J; Novello, S; Peric, A; Reck, M; Remon, J; Wasag, B | 1 |
| Chatterjee, A; Chau, I; Chong, IY; Clark, C; Dahle-Smith, A; Dutton, SJ; Elyan, S; Falk, SJ; Ferry, DR; Fyfe, DW; Garcia-Alonso, A; Harrison, M; Mansoor, W; Massie, D; Miedzybrodzka, Z; Murray, GI; Osborne, A; Petty, RD; Roberts, C; Stevenson, DAJ; Thompson, J; Wadsley, J | 1 |
| Ho, CC; Hsiue, EH; Lee, JH; Liao, WY; Lin, CC; Shih, JY; Wu, TH; Yang, JC; Yu, CJ | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
1 review(s) available for gefitinib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
Topics: Biopsy; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Response Evaluation Criteria in Solid Tumors; Salvage Therapy | 2021 |
2 trial(s) available for gefitinib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolinones; Response Evaluation Criteria in Solid Tumors | 2021 |
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Substitution; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Liquid Biopsy; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Research Design; Response Evaluation Criteria in Solid Tumors | 2017 |
5 other study(ies) available for gefitinib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase III as Topic; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors; Signal Transduction; Single-Blind Method; Survival Rate | 2017 |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors | 2018 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome | 2015 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |